Pharmerica Corporation (NYSE: PMC) Stock Competitors & Peer Comparison

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while SIRO trades at $109.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas SIRO's P/E ratio is 31.88. In terms of profitability, PMC's ROE is +0.04%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, PMC is less volatile compared to SIRO. This indicates lower risk in terms of short-term price fluctuations for PMC.Check SIRO's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, HIMS has a market cap of 7B. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while HIMS trades at $31.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas HIMS's P/E ratio is -315.90. In terms of profitability, PMC's ROE is +0.04%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, PMC is less volatile compared to HIMS. This indicates lower risk in terms of short-term price fluctuations for PMC.Check HIMS's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, MMED has a market cap of 5.5B. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while MMED trades at $19.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas MMED's P/E ratio is -25.29. In terms of profitability, PMC's ROE is +0.04%, compared to MMED's ROE of -0.14%. Regarding short-term risk, PMC is less volatile compared to MMED. This indicates lower risk in terms of short-term price fluctuations for PMC.Check MMED's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, OMCL has a market cap of 1.7B. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while OMCL trades at $36.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas OMCL's P/E ratio is 19.27. In terms of profitability, PMC's ROE is +0.04%, compared to OMCL's ROE of +0.03%. Regarding short-term risk, PMC is less volatile compared to OMCL. This indicates lower risk in terms of short-term price fluctuations for PMC.Check OMCL's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, DRTS has a market cap of 1.2B. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while DRTS trades at $13.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas DRTS's P/E ratio is -19.61. In terms of profitability, PMC's ROE is +0.04%, compared to DRTS's ROE of -0.73%. Regarding short-term risk, PMC is less volatile compared to DRTS. This indicates lower risk in terms of short-term price fluctuations for PMC.Check DRTS's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, MLAB has a market cap of 574.4M. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while MLAB trades at $102.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas MLAB's P/E ratio is 10.36. In terms of profitability, PMC's ROE is +0.04%, compared to MLAB's ROE of +0.04%. Regarding short-term risk, PMC is less volatile compared to MLAB. This indicates lower risk in terms of short-term price fluctuations for PMC.Check MLAB's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, LAB has a market cap of 313.2M. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while LAB trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas LAB's P/E ratio is -11.43. In terms of profitability, PMC's ROE is +0.04%, compared to LAB's ROE of -0.18%. Regarding short-term risk, PMC is less volatile compared to LAB. This indicates lower risk in terms of short-term price fluctuations for PMC.Check LAB's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, STXS has a market cap of 139M. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while STXS trades at $1.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas STXS's P/E ratio is -8.35. In terms of profitability, PMC's ROE is +0.04%, compared to STXS's ROE of -1.53%. Regarding short-term risk, PMC is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for PMC.Check STXS's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, FONR has a market cap of 117.8M. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while FONR trades at $19.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas FONR's P/E ratio is 19.09. In terms of profitability, PMC's ROE is +0.04%, compared to FONR's ROE of +0.04%. Regarding short-term risk, PMC is more volatile compared to FONR. This indicates higher risk in terms of short-term price fluctuations for PMC.Check FONR's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, LNSR has a market cap of 74.2M. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while LNSR trades at $6.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas LNSR's P/E ratio is 6.16. In terms of profitability, PMC's ROE is +0.04%, compared to LNSR's ROE of -5.15%. Regarding short-term risk, PMC is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for PMC.Check LNSR's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while KDLY trades at $11.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas KDLY's P/E ratio is -15.48. In terms of profitability, PMC's ROE is +0.04%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, PMC is less volatile compared to KDLY. This indicates lower risk in terms of short-term price fluctuations for PMC.Check KDLY's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while NEUE trades at $6.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas NEUE's P/E ratio is -0.38. In terms of profitability, PMC's ROE is +0.04%, compared to NEUE's ROE of +0.05%. Regarding short-term risk, PMC is less volatile compared to NEUE. This indicates lower risk in terms of short-term price fluctuations for PMC.Check NEUE's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, SNWV has a market cap of 50.6M. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while SNWV trades at $5.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas SNWV's P/E ratio is 17.82. In terms of profitability, PMC's ROE is +0.04%, compared to SNWV's ROE of +17.28%. Regarding short-term risk, PMC is less volatile compared to SNWV. This indicates lower risk in terms of short-term price fluctuations for PMC.Check SNWV's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, EKSO has a market cap of 38.6M. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while EKSO trades at $15.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas EKSO's P/E ratio is -3.11. In terms of profitability, PMC's ROE is +0.04%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, PMC is less volatile compared to EKSO. This indicates lower risk in terms of short-term price fluctuations for PMC.Check EKSO's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, BEAT has a market cap of 29.1M. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while BEAT trades at $0.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas BEAT's P/E ratio is -0.94. In terms of profitability, PMC's ROE is +0.04%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, PMC is less volatile compared to BEAT. This indicates lower risk in terms of short-term price fluctuations for PMC.Check BEAT's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, STSSW has a market cap of 839.4K. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while STSSW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas STSSW's P/E ratio is -0.03. In terms of profitability, PMC's ROE is +0.04%, compared to STSSW's ROE of N/A. Regarding short-term risk, PMC is more volatile compared to STSSW. This indicates higher risk in terms of short-term price fluctuations for PMC.Check STSSW's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, ABCO has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while ABCO trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas ABCO's P/E ratio is 0.52. In terms of profitability, PMC's ROE is +0.04%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, PMC is less volatile compared to ABCO. This indicates lower risk in terms of short-term price fluctuations for PMC.Check ABCO's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, SCAI has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while SCAI trades at $55.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas SCAI's P/E ratio is 63.45. In terms of profitability, PMC's ROE is +0.04%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, PMC is less volatile compared to SCAI. This indicates lower risk in terms of short-term price fluctuations for PMC.Check SCAI's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, LDR has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while LDR trades at $67.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas LDR's P/E ratio is N/A. In terms of profitability, PMC's ROE is +0.04%, compared to LDR's ROE of +1.17%. Regarding short-term risk, PMC is more volatile compared to LDR. This indicates higher risk in terms of short-term price fluctuations for PMC.Check LDR's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, MZOR has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while MZOR trades at $58.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas MZOR's P/E ratio is -70.18. In terms of profitability, PMC's ROE is +0.04%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, PMC is more volatile compared to MZOR. This indicates higher risk in terms of short-term price fluctuations for PMC.Check MZOR's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, MEDC has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while MEDC trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas MEDC's P/E ratio is N/A. In terms of profitability, PMC's ROE is +0.04%, compared to MEDC's ROE of N/A. Regarding short-term risk, PMC is less volatile compared to MEDC. This indicates lower risk in terms of short-term price fluctuations for PMC.Check MEDC's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, STJ has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while STJ trades at $80.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas STJ's P/E ratio is 34.69. In terms of profitability, PMC's ROE is +0.04%, compared to STJ's ROE of +0.21%. Regarding short-term risk, PMC is less volatile compared to STJ. This indicates lower risk in terms of short-term price fluctuations for PMC.Check STJ's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, LPNT has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while LPNT trades at $64.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas LPNT's P/E ratio is 67.44. In terms of profitability, PMC's ROE is +0.04%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, PMC is more volatile compared to LPNT. This indicates higher risk in terms of short-term price fluctuations for PMC.Check LPNT's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, CYNO has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while CYNO trades at $66.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas CYNO's P/E ratio is 105.35. In terms of profitability, PMC's ROE is +0.04%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, PMC is more volatile compared to CYNO. This indicates higher risk in terms of short-term price fluctuations for PMC.Check CYNO's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, ABAX has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while ABAX trades at $83.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas ABAX's P/E ratio is 70.62. In terms of profitability, PMC's ROE is +0.04%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, PMC is more volatile compared to ABAX. This indicates higher risk in terms of short-term price fluctuations for PMC.Check ABAX's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, EVHC has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while EVHC trades at $45.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas EVHC's P/E ratio is -3.20. In terms of profitability, PMC's ROE is +0.04%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, PMC is more volatile compared to EVHC. This indicates higher risk in terms of short-term price fluctuations for PMC.Check EVHC's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, COTV has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while COTV trades at $44.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas COTV's P/E ratio is 26.51. In terms of profitability, PMC's ROE is +0.04%, compared to COTV's ROE of +0.14%. Regarding short-term risk, PMC is more volatile compared to COTV. This indicates higher risk in terms of short-term price fluctuations for PMC.Check COTV's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, AMSG has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while AMSG trades at $67.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas AMSG's P/E ratio is N/A. In terms of profitability, PMC's ROE is +0.04%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, PMC is less volatile compared to AMSG. This indicates lower risk in terms of short-term price fluctuations for PMC.Check AMSG's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, SPNC has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while SPNC trades at $38.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas SPNC's P/E ratio is -24.03. In terms of profitability, PMC's ROE is +0.04%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, PMC is more volatile compared to SPNC. This indicates higher risk in terms of short-term price fluctuations for PMC.Check SPNC's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, DSCI has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while DSCI trades at $7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas DSCI's P/E ratio is -0.02. In terms of profitability, PMC's ROE is +0.04%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, PMC is less volatile compared to DSCI. This indicates lower risk in terms of short-term price fluctuations for PMC.Check DSCI's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, SPAN has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while SPAN trades at $29.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas SPAN's P/E ratio is N/A. In terms of profitability, PMC's ROE is +0.04%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, PMC is less volatile compared to SPAN. This indicates lower risk in terms of short-term price fluctuations for PMC.Check SPAN's competition here

Pharmerica Corporation (NYSE: PMC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PMC stands at 0. In comparison, EXAC has a market cap of 0. Regarding current trading prices, PMC is priced at $29.25 on the NYSE, while EXAC trades at $49.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PMC currently has a P/E ratio of 47.95, whereas EXAC's P/E ratio is 3510.33. In terms of profitability, PMC's ROE is +0.04%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, PMC is more volatile compared to EXAC. This indicates higher risk in terms of short-term price fluctuations for PMC.Check EXAC's competition here